Table 3.
Secondary solid malignancies and precancerous lesions after total body irradiation-based conditioning (n = 89)
| No. | Secondary malignancies (SMs), precancerous lesions | TBI dose | Years from TBI to SMs, † death due to SMs |
Age at TBI | Sex | Chronic GVHD requiring systemic immunosuppression, organs of involvement |
Smoker |
|---|---|---|---|---|---|---|---|
| Non-squamous cell carcinomas (non-SCCs) in 8 patients | |||||||
| 419 | Mucoepidermoid cancer, lower lip, T1 G1 R0 | TBI 4 Gy | 11.69 | 26.2 | male | yes, skin. liver, joints | no |
| 266 | Medullary thyroid cancer, pT1a pN0 L0 V0 R0 | TBI 4 Gy | 5.33 | 40.2 | male | yes, skin, oral mucosa, eyes | no |
| 266 | Cutaneous basal cell carcinoma, face | TBI 4 Gy | 5.33 | 40.2 | male | yes, skin, oral mucosa, eyes | no |
| 19 | Mucoepidermoid carcinoma, major salivary gland, pT2 pN1 cM0 | TBI 8 Gy | 9.63 | 22.8 | male | yes, oral mucosa, eyes, gastrointestinal, liver | no |
| 240 | Cutaneous basal cell carcinoma, neck | TBI 8 Gy | 12.73 | 45.8 | male | no | yes |
| 240 | Cutaneous basal cell carcinoma, face | TBI 8 Gy | 12.73 | 45.8 | male | no | yes |
| 290 | Pleomorphic undifferentiated sarcoma, pT3 pN1 cM0 R1 * | TBI 8 Gy | 0.88, † death after 0.74 years | 51.6 | female | yes, gastrointestinal | no |
| 117 | Papillary thyroid cancer, pT1a L0 V0 R0 | TBI 4 Gy | 6.02 | 19.4 | male | yes, skin, eyes | no |
| 96 | Prostate cancer, adenocarcinoma | TBI 4 Gy | 12.45, † death after 3.55 years | 60.2 | male | no | no |
| 96 | Cutaneous basal cell carcinoma, face | TBI 4 Gy | 16.0 | 60.2 | male | no | no |
| 307 | Cutaneous basal cell carcinoma, face | TBI 8 Gy | 14.5 | 38.6 | female | yes, skin | no |
| 307 | Cutaneous basal cell carcinoma, face | TBI 8 Gy | 14.5 | 38.6 | female | yes, skin | no |
| 307 | Cutaneous basal cell carcinoma, face | TBI 8 Gy | 15.2 | 38.6 | female | yes, skin | no |
| 307 | Cutaneous basal cell carcinoma, face | TBI 8 Gy | 16.7 | 38.6 | female | yes, skin | no |
| 307 | Cutaneous eccine carcinoma, face | TBI 8 Gy | 18.2 | 38.6 | female | yes, skin | no |
| Squamous cell carcinomas (SCCs) in 3 patients | |||||||
| 428 | Cutaneous squamous cell carcinoma, face | TBI 8 Gy | 3.20 | 52.7 | male | yes, skin | no |
| 428 | Cutaneous squamous cell carcinoma, face | TBI 8 Gy | 3.50 | 52.7 | male | yes, skin | no |
| 432 | Cutaneous squamous cell carcinoma, face | TBI 8 Gy | 16.98 | 22.9 | male | no | yes |
| 9 | Squamous cell carcinoma, lip, pT1 cN0 cM0 | TBI 8 Gy | 9.40 | 20.3 | male | yes, skin, oral mucosa, CNS, gastrointestinal | no |
| Precancerous lesions, carcinomas in situ in 3 patients | |||||||
| 33 | Severe intraepithelial neoplasia of the vagina (VIN3) | TBI 8 Gy | 7.41 | 25.1 | female | yes, skin, oral mucosa, liver, CNS, eyes, vaginal | no |
| 307 | Cutaneous carcinoma in situ, ear | TBI 8 Gy | 18.22 | 38.6 | female | yes, skin | no |
| 412 | Cutaneous carcinoma in situ, skin | TBI 4 Gy | 3.79 | 48.6 | male | yes, skin, oral mucosa, lung, eyes | no |
* It was assumed that the pleomorphic undifferentiated sarcoma which appeared within less than a year after TBI was present at the time of allo-HSCT. Therefore, this patient was excluded from further analyses